AU2018282905B2 - Bisphosphocin gel formulations and uses thereof - Google Patents

Bisphosphocin gel formulations and uses thereof Download PDF

Info

Publication number
AU2018282905B2
AU2018282905B2 AU2018282905A AU2018282905A AU2018282905B2 AU 2018282905 B2 AU2018282905 B2 AU 2018282905B2 AU 2018282905 A AU2018282905 A AU 2018282905A AU 2018282905 A AU2018282905 A AU 2018282905A AU 2018282905 B2 AU2018282905 B2 AU 2018282905B2
Authority
AU
Australia
Prior art keywords
formulation
weight
patient
present disclosure
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018282905A
Other languages
English (en)
Other versions
AU2018282905A1 (en
Inventor
Keith Arthur Johnson
Steven A. Kates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lakewood Amedex Inc
Original Assignee
Lakewood Amedex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lakewood Amedex Inc filed Critical Lakewood Amedex Inc
Publication of AU2018282905A1 publication Critical patent/AU2018282905A1/en
Application granted granted Critical
Publication of AU2018282905B2 publication Critical patent/AU2018282905B2/en
Priority to AU2022224829A priority Critical patent/AU2022224829B2/en
Priority to AU2024202211A priority patent/AU2024202211B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Ophthalmology & Optometry (AREA)
AU2018282905A 2017-06-12 2018-06-12 Bisphosphocin gel formulations and uses thereof Ceased AU2018282905B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022224829A AU2022224829B2 (en) 2017-06-12 2022-09-02 Bisphosphocin gel formulations and uses thereof
AU2024202211A AU2024202211B2 (en) 2017-06-12 2024-04-05 Bisphosphocin gel formulations and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518262P 2017-06-12 2017-06-12
US62/518,262 2017-06-12
PCT/US2018/037151 WO2018231863A1 (en) 2017-06-12 2018-06-12 Bisphosphocin gel formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022224829A Division AU2022224829B2 (en) 2017-06-12 2022-09-02 Bisphosphocin gel formulations and uses thereof

Publications (2)

Publication Number Publication Date
AU2018282905A1 AU2018282905A1 (en) 2019-12-19
AU2018282905B2 true AU2018282905B2 (en) 2022-06-02

Family

ID=64562861

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018282905A Ceased AU2018282905B2 (en) 2017-06-12 2018-06-12 Bisphosphocin gel formulations and uses thereof
AU2022224829A Active AU2022224829B2 (en) 2017-06-12 2022-09-02 Bisphosphocin gel formulations and uses thereof
AU2024202211A Active AU2024202211B2 (en) 2017-06-12 2024-04-05 Bisphosphocin gel formulations and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022224829A Active AU2022224829B2 (en) 2017-06-12 2022-09-02 Bisphosphocin gel formulations and uses thereof
AU2024202211A Active AU2024202211B2 (en) 2017-06-12 2024-04-05 Bisphosphocin gel formulations and uses thereof

Country Status (14)

Country Link
US (5) US11096954B2 (enExample)
EP (2) EP3638251B1 (enExample)
JP (2) JP7148994B2 (enExample)
KR (3) KR20260035292A (enExample)
CN (1) CN110753549A (enExample)
AU (3) AU2018282905B2 (enExample)
BR (2) BR122021011439B1 (enExample)
CA (1) CA3066722A1 (enExample)
DK (1) DK3638251T3 (enExample)
ES (1) ES2981923T3 (enExample)
FI (1) FI3638251T3 (enExample)
MX (1) MX2019014772A (enExample)
PT (1) PT3638251T (enExample)
WO (1) WO2018231863A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US12030908B2 (en) 2017-03-10 2024-07-09 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
KR102684529B1 (ko) * 2017-03-10 2024-07-12 레이크우드 아메덱스, 인크. 항미생물 화합물, 조성물, 및 그의 용도
US11377468B2 (en) 2017-03-10 2022-07-05 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
KR20260035292A (ko) 2017-06-12 2026-03-12 레이크우드 아메덱스, 인크. 비스포스포신 겔 제제 및 이의 용도
CN112839662A (zh) 2018-10-17 2021-05-25 莱克伍德阿美达克斯股份有限公司 用于治疗口腔粘膜炎的方法和组合物
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
MX2023008829A (es) * 2021-07-22 2023-08-10 Lakewood Amedex Inc Metodos para preparar bisfosfocinas.
WO2025179296A1 (en) * 2024-02-22 2025-08-28 Lakewood Amedex, Inc. Crystalline forms of nu-3 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110135713A1 (en) * 1998-12-30 2011-06-09 Lakewood-Amedex, Inc. Antimicrobial and Antiviral Compounds and Methods for Their Use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
KR830005852A (ko) * 1980-07-18 1983-09-14 미첼 페터 잭슨 피부와 점막의 비루스 감염치료에 적합한 국소치료제의 제조방법
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
DE3542516A1 (de) 1985-12-02 1987-06-04 Henkel Kgaa Desinfektionsmittel
US5266310A (en) 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
US5153230A (en) 1989-10-06 1992-10-06 Perfective Cosmetics, Inc. Topical skin cream composition
US5167950A (en) 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
US5208015A (en) 1991-07-23 1993-05-04 Bristol-Myers Squibb Company Topical anti-fungal agents having anti-inflammatory activity
DE4333385C2 (de) 1993-09-30 1997-01-30 Friedrich A Spruegel Flächendesinfektions- und Reinigungsmittel
EP0748203A1 (en) * 1994-03-11 1996-12-18 The Procter & Gamble Company LOW pH, HYDROLYTICALLY STABLE, COSMETIC COMPOSITIONS CONTAINING ACIDIC ACTIVES
FR2718022B1 (fr) 1994-04-01 1996-04-26 Roussel Uclaf Compositions cosmétiques ou dermatologiques et leur préparation.
FR2722102B1 (fr) 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
US5843998A (en) 1997-06-30 1998-12-01 Song; Jin Skin blemish treatment
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US6627215B1 (en) 1998-12-30 2003-09-30 Oligos Etc. Inc. Devices for improved wound management
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
WO2003032909A2 (en) * 2001-10-18 2003-04-24 Ilex Products, Inc. Methods of treating skin with diphosphonate derivatives
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
CN1687100A (zh) * 2005-04-05 2005-10-26 奥林格斯技术有限公司 修饰性核苷酸及其用途
EP2149375A1 (en) 2008-07-28 2010-02-03 Despharma Kft. Compositions for the treatment of dermatological diseases, and uses thereof
BRPI1006729B1 (pt) 2009-04-13 2021-10-05 Sulur Subramaniam Vanangamudi Creme medicinal de ácido fusídico preparado utilizando fusidato de sódio e incorporando um biopolímero e seu processo de preparação
WO2015075406A1 (en) * 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
FR3041540B1 (fr) 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante a rincer, contenant de l'ivermectine.
KR20260035292A (ko) 2017-06-12 2026-03-12 레이크우드 아메덱스, 인크. 비스포스포신 겔 제제 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110135713A1 (en) * 1998-12-30 2011-06-09 Lakewood-Amedex, Inc. Antimicrobial and Antiviral Compounds and Methods for Their Use

Also Published As

Publication number Publication date
BR122021011439B1 (pt) 2022-03-29
US20230125677A1 (en) 2023-04-27
AU2018282905A1 (en) 2019-12-19
US20210361689A1 (en) 2021-11-25
BR112019026073B1 (pt) 2021-11-03
AU2022224829A1 (en) 2022-09-29
ES2981923T3 (es) 2024-10-11
KR20260035292A (ko) 2026-03-12
JP2022183154A (ja) 2022-12-08
FI3638251T3 (fi) 2024-04-29
EP3638251A1 (en) 2020-04-22
KR20200014904A (ko) 2020-02-11
EP3638251A4 (en) 2021-03-10
EP4241769A3 (en) 2023-11-08
KR20230031370A (ko) 2023-03-07
AU2022224829B2 (en) 2024-12-05
JP2020523322A (ja) 2020-08-06
US20200360415A1 (en) 2020-11-19
US11096954B2 (en) 2021-08-24
JP7470449B2 (ja) 2024-04-18
AU2024202211A1 (en) 2024-05-02
DK3638251T3 (da) 2024-05-13
NZ759577A (en) 2025-10-31
EP3638251B1 (en) 2024-03-06
US20180353529A1 (en) 2018-12-13
MX2019014772A (es) 2020-02-07
WO2018231863A1 (en) 2018-12-20
AU2024202211B2 (en) 2025-12-04
PT3638251T (pt) 2024-05-22
US20250262234A1 (en) 2025-08-21
JP7148994B2 (ja) 2022-10-06
CN110753549A (zh) 2020-02-04
CA3066722A1 (en) 2018-12-20
BR112019026073A2 (pt) 2020-06-30
EP4241769A2 (en) 2023-09-13
US12156883B2 (en) 2024-12-03

Similar Documents

Publication Publication Date Title
AU2022224829B2 (en) Bisphosphocin gel formulations and uses thereof
US12264170B2 (en) Antimicrobial organosilanes
EP2496215B1 (en) Antimicrobial and anti-acne formulations
US20260091049A1 (en) Halide-free ammonium silanes
WO2020081839A1 (en) Methods and compositions for treating oral mucositis
HK40099007A (en) Bisphosphocin gel formulations and uses thereof
US20250034184A1 (en) Quaternary phosphonium compounds and uses thereof
HK40025987B (en) Bisphosphocin gel formulations and uses thereof
HK40025987A (en) Bisphosphocin gel formulations and uses thereof
HK40078560A (en) Antimicrobial organosilanes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired